DAT (chemotherapy)

DAT in the context of chemotherapy is an acronym that means a chemotherapy regimen most often used as an induction regimen in acute myelogenous leukemia, usually for those who are refractory to the standard "7+3" induction regimen or who has relapsed. But this regimen also can be used as primary, first-line induction therapy.

DAT
Specialty	Oncology

The DAT regimen consists of:

1. Daunorubicin - an anthracycline antibiotic that is able to intercalate DNA, thus disrupting cell division and preventing mitosis;
2. Ara-C (cytarabine) - an antimetabolite;
3. Thioguanine - another antimetabolite.^[1]

Dosing regimen

Drug	Dose	Mode	Days
Ara-C (cytarabine)	200 mg/m2	IV push every 12 hours in 2 divided doses (100 mg/m2 each)	Days 1-10
Daunorubicin	50 mg/m2	IV slow push	Days 1, 3 and 5
Thioguanine	200 mg/m2	PO every 12 hours in 2 divided doses (100 mg/m2 each)	Days 1-10